Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Erasmus Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06888063CT.gov Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery | — | Recruiting | — | — | — |
NCT05286814CT.gov PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | — | Recruiting | — | — | — |
NCT04251715CT.gov mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intrahepatic Cholangiocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Floxuridine (this asset) | Erasmus Medical Center | P2 | CCC · 51 |
| Nivolumab | Virogin Biotech Canada Ltd | P2 | BB |
| Durvalumab | West China Hospital | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Shanghai 6th People's Hospital | P2 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | B |
| Atezolizumab | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | TriSalus Life Sciences, Inc. | P2 | B |
| Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | P2 | B |
| Pembrolizumab | Shanghai 6th People's Hospital | P1/2 | B |
+42 more in the Intrahepatic Cholangiocarcinoma cohort
Other indications for Floxuridine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Carcinoma | — | P2 | BBB · 72 |
| Rectal Carcinoma | — | P2 | BBB · 72 |
| Colon Adenocarcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Floxuridine in Intrahepatic Cholangiocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/floxuridine-intrahepatic-cholangiocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →